Sheet

→	+	١
	T .	

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complet if Known		
				Application Number	Int'l App.: PCT/US99/25692	
INFORMATION DISCLOSURE				Filing Date	Int'l App. Filed: 2 Nov 1999	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	CHIEN, KENNETH et al	
				Group Art Unit	UNKNOWN	
(us	se as many she	ets as ne	cessary) .	Examiner Name	UNKNOWN	
heet	1	of	2	Attorney Docket Number	6627-PA9025	

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Number	Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
140.	1	5,652,12	.2	FRANKEL, et al.	07-29-1997				
PAD	2	5,968,95		HAIKALA, et al.	10-19-1999				
7									
		····							
									
		<u> </u>							
 		1.7			+				
									
									
 									
		•							
					<u> </u>				
					_				
	<u> </u>				<u> </u>				

				FOR	EIGN PATENT DOCUMEN	rs		
Examiner Cite		<u> </u>	Foreign Patent Docum		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials	No.1	Office ³	Number ⁴	Kind Code [®] (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
PAD	3		WO 97/37224	Al	MEDICAL RESEARCH COUNCIL	10-09-1997		
PAD	4		WO 99/04636	A1	THE GENERAL HOSPITAL CORP.	02-04-1999		
DAD	5		WO 99/30696	A1	ORION CORPORATION	06-24-1999		\prod
	6_		FR 2,753,722		SMITHKLINE BEECHAM LAB.	-03-27-1998		
					,			↓_
							· · · · · · · · · · · · · · · · · · ·	\bot
					· · · · · · · · · · · · · · · · · · ·	ļ		╀
		├						╀
		 		_		 	·····	╀

	ate onsidered 6/1/03
--	-------------------------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



10 loghish

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

lease type a plus sign (+) inside this box	→	4
--	----------	---

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449B/l	PTO		C mplet if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Int'l App.: PCT/US99/25692	
				Filing Date	Int'l App. Filed: 2 Nov 1999	
				First Named Inventor	CHIEN, KENNETH et al	
				Group Art Unit	UNKNOWN	
(use as many sheets as necessary)			s as necessary)	Examiner Name	UNKNOWN	
Sheet	2	of	2	Attorney Docket Number	6627-PA9025	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PAD	7	DILLMANN, Wolfgang H., Influences of Increased Expression of the Ca2+ ATPase of the Sarcoplasmic Reticulum by a Transgenic Approach on Cardiac Contractility, Ann. New York Acad Sci., 1998, 853:43-48.	
PAD	8	KOSS, Kimberly L. and KRANIAS, Evangelia G., Phospholamban: A Prominent Regulator of Myocardial Contractility, Circ Res, 79:1059-63.	
PAD	9 	HE, Huaping, et al., Influence of an Antisense Phospholmaban Trasncribed By An Adenoviral Vector on Ca2+ ATPase in Cardiac Myocytes, J. Mol. Cell. Cardiol., 1997, 29:A181.	
740 .	10 I,	HE, Huaping, et al., Effects of Mutant and Antisense RNA of Phospholamban on SR Ca2+-ATPase Activity and Cardiac Myocyte Contractility, Circulation, 1999, 100:974-80.	: 1
PAD.	11 (,	MINAMISAWA, Susumu, et al., Chronic Phospholamban-Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy, Cell, 1999, 99:313-22.	
PAS	12	TADA, Michihiko and TOYOFUKU, Toshihiko, Molecular Regulation of Phospholamban Function and Expression, TCM, 1998, 8:330-40.	
PAD	13	TOYOFKU, Toshihiko, et al., Amino Acids Glu2 to Ile18 in the Cytoplasmic Domain of Phospholamban Are Essential for Functional Association with the Ca2+ -ATPase of Sarcoplasmic Reticulum, The Journal of Biological Chemistry, 1994, 269:3088-94.	
	,		
7			
	·		

Examiner	DATO ICIA ADILECT	Date	6/1/80
Signature	MARICIA ADULY Y	Considered	1.1.3

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.